The FDA approved certolizumab pegol (Cimzia, UCB) injection for treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation.
Certolizumab injection is the first FDA-approved treatment for adults with nr-axSpA and “fulfills an unmet need” for these patients, Nikolay Nikolov, MD, of the Division of Pulmonary, Allergy, and Rheumatology Products in the FDA’s Center for Drug Evaluation and Research, stated in a newsMARCH 28, 2019